Movatterモバイル変換


[0]ホーム

URL:


SG11201908719QA - Biomarkers and car t cell therapies with enhanced efficacy - Google Patents

Biomarkers and car t cell therapies with enhanced efficacy

Info

Publication number
SG11201908719QA
SG11201908719QASG11201908719QASG11201908719QASG 11201908719Q ASG11201908719Q ASG 11201908719QASG 11201908719Q ASG11201908719Q ASG 11201908719QASG 11201908719Q ASG11201908719Q ASG 11201908719QA
Authority
SG
Singapore
Prior art keywords
international
rule
pct
cell therapies
methods
Prior art date
Application number
Inventor
Joseph Fraietta
Jan Melenhorst
Original Assignee
Novartis Ag
Univ Pennsylvania
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag, Univ PennsylvaniafiledCriticalNovartis Ag
Publication of SG11201908719QApublicationCriticalpatent/SG11201908719QA/en

Links

Classifications

Landscapes

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 27 September 2018 (27.09.2018) WIPO I PCT onion °nolo oloinomll n ono oimIE (10) International Publication Number WO 2018/175733 Al (51) International Patent Classification: A61K 39/00 (2006.01) C07K 16/28 (2006.01) (21) International Application Number: PCT/US2018/023785 (22) International Filing Date: 22 March 2018 (22.03.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/474,991 22 March 2017 (22.03.2017) US 62/621,356 24 January 2018 (24.01.2018) US (71) Applicants: NOVARTIS AG [CH/CH]; Lichtstrasse 35, 4056 Basel (CH). THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA [US/US]; 3160 Chestnut Street, Suite 200, Philadelphia, PA 19104 (US). (72) Inventors: FRAIETTA, Joseph, A.; 18 Saddle Lane, Cherry Hill, NJ 08002 (US). MELENHORST, Jan, J.; 11 Exton Circle, Cherry Hill, NJ 08003 (US). (74) Agent: COLLAZO, Diana M. et al.; Lando & Anastasi, LLP, Riverfront Office Park, One Main Street, Suite 1100, Cambridge, MA 02142 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a)) 1-1 (54) Title: BIOMARKERS AND CAR T CELL THERAPIES WITH ENHANCED EFFICACY (57) : The invention provides compositions and methods improved CART cell therapies. Specifically, the invention provides 0 cells with altered expression and/or function of one or more genes, e.g., associated with Tet2, and methods of use therefore. The \" invention further provides inhibitors of the one or more genes and methods of use therefore in connection with CART cells.
SG11201908719Q2017-03-222018-03-22Biomarkers and car t cell therapies with enhanced efficacySG11201908719QA (en)

Applications Claiming Priority (3)

Application NumberPriority DateFiling DateTitle
US201762474991P2017-03-222017-03-22
US201862621356P2018-01-242018-01-24
PCT/US2018/023785WO2018175733A1 (en)2017-03-222018-03-22Biomarkers and car t cell therapies with enhanced efficacy

Publications (1)

Publication NumberPublication Date
SG11201908719QAtrue SG11201908719QA (en)2019-10-30

Family

ID=62104357

Family Applications (1)

Application NumberTitlePriority DateFiling Date
SG11201908719QSG11201908719QA (en)2017-03-222018-03-22Biomarkers and car t cell therapies with enhanced efficacy

Country Status (12)

CountryLink
US (1)US20200087376A1 (en)
EP (1)EP3600392A1 (en)
JP (2)JP2020513828A (en)
KR (1)KR20190127892A (en)
CN (1)CN110831619A (en)
AU (1)AU2018240295A1 (en)
BR (1)BR112019019426A2 (en)
CA (1)CA3057306A1 (en)
IL (1)IL269412A (en)
RU (1)RU2019133286A (en)
SG (1)SG11201908719QA (en)
WO (1)WO2018175733A1 (en)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
US9273283B2 (en)*2009-10-292016-03-01The Trustees Of Dartmouth CollegeMethod of producing T cell receptor-deficient T cells expressing a chimeric receptor
KR102685501B1 (en)2013-02-202024-07-17노파르티스 아게Treatment of cancer using humanized anti-egfrviii chimeric antigen receptor
ES2769574T3 (en)2013-03-152020-06-26Michael C Milone Recognition of cytotoxic cells with chimeric receptors for adoptive immunotherapy
UY35468A (en)2013-03-162014-10-31Novartis Ag CANCER TREATMENT USING AN ANTI-CD19 CHEMERIC ANTIGEN RECEIVER
EP3087101B1 (en)2013-12-202024-06-05Novartis AGRegulatable chimeric antigen receptor
EP4303229A3 (en)2014-01-212024-04-17Novartis AGEnhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
WO2016014576A1 (en)2014-07-212016-01-28Novartis AgTreatment of cancer using a cd33 chimeric antigen receptor
US11542488B2 (en)2014-07-212023-01-03Novartis AgSortase synthesized chimeric antigen receptors
AU2015292744C1 (en)2014-07-212021-01-21Novartis AgTreatment of cancer using humanized anti-BCMA chimeric antigen receptor
RU2020117196A (en)2014-08-192020-10-15Новартис Аг CHIMERIC ANTIGENIC RECEPTOR (CAR) AGAINST CD123 FOR USE IN THE TREATMENT OF MALIGNANT TUMORS
US11459390B2 (en)2015-01-162022-10-04Novartis AgPhosphoglycerate kinase 1 (PGK) promoters and methods of use for expressing chimeric antigen receptor
US11161907B2 (en)2015-02-022021-11-02Novartis AgCar-expressing cells against multiple tumor antigens and uses thereof
PT3280729T (en)2015-04-082022-08-01Novartis AgCd20 therapies, cd22 therapies, and combination therapies with a cd19 chimeric antigen receptor (car) - expressing cell
JP7114457B2 (en)2015-04-172022-08-08ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア Methods for Improving Efficacy and Growth of Chimeric Antigen Receptor-Expressing Cells
EP3286211A1 (en)2015-04-232018-02-28Novartis AGTreatment of cancer using chimeric antigen receptor and protein kinase a blocker
CN109476722A (en)2015-07-212019-03-15诺华股份有限公司 Methods for improving the efficacy and expansion of immune cells
US11667691B2 (en)2015-08-072023-06-06Novartis AgTreatment of cancer using chimeric CD3 receptor proteins
US11747346B2 (en)2015-09-032023-09-05Novartis AgBiomarkers predictive of cytokine release syndrome
NZ782857A (en)2015-12-042025-08-29Novartis AgCompositions and methods for immunooncology
WO2017165683A1 (en)2016-03-232017-09-28Novartis AgCell secreted minibodies and uses thereof
EP3523331A1 (en)2016-10-072019-08-14Novartis AGChimeric antigen receptors for the treatment of cancer
EP3574005B1 (en)2017-01-262021-12-15Novartis AGCd28 compositions and methods for chimeric antigen receptor therapy
EA201992232A1 (en)2017-03-222020-05-14Новартис Аг COMPOSITIONS AND METHODS FOR IMMUNOUNCOLOGY
MX2020004013A (en)2017-10-182021-01-08Novartis AgCompositions and methods for selective protein degradation.
KR20210020932A (en)2018-06-132021-02-24노파르티스 아게 BCMA chimeric antigen receptor and uses thereof
CN109517073A (en)*2018-11-302019-03-26北京泽勤生物医药有限公司A kind of fusogenic peptide of targeting therapy on tumor and its application
US20220017888A1 (en)*2018-12-112022-01-20Kyoto UniversityMethod for inducing deletion in genomic dna
US20220160751A1 (en)*2019-04-022022-05-26Yale UniversityMethods of treatment of diseases and disorders associated with increased tet level, increased h19 level, increased level of tgf signaling, or any combination thereof
AU2020264484A1 (en)2019-05-012021-11-04Adoc Ssf, LlcCompositions and methods for the treatment of cancer using a CDB engineered T cell therapy
WO2021044378A1 (en)2019-09-062021-03-11Crispr Therapeutics AgGenetically engineered t cells having improved persistence in culture
IL293215A (en)2019-11-262022-07-01Novartis Ag Chimeric antigen receptors that bind bcma and cd19 and their uses
EP4065157A1 (en)2019-11-262022-10-05Novartis AGCd19 and cd22 chimeric antigen receptors and uses thereof
WO2021127261A1 (en)*2019-12-172021-06-24The General Hospital CorporationEngineered immune cells with reduced toxicity and uses thereof
EP4105232A4 (en)*2020-02-142023-10-11Beijing Yongtai Ruike Biotechnology Company Ltd IMMUNE CELLS OVEREXPRESSING THE EXTERNALLY INTRODUCED CELL SIGNALING REGULATORY FACTOR AND THEIR USE
CN115461070A (en)*2020-03-182022-12-09斯坦福大学托管董事会 Upregulation of cathepsin gene expression as an adjunct to other treatments for disease
US12240899B2 (en)2020-06-222025-03-04Ngm Biopharmaceuticals, Inc.LAIR-1-binding agents and methods of use thereof
IL300489A (en)2020-08-212023-04-01Novartis AgCompositions and methods for in vivo generation of car expressing cells
US12152251B2 (en)2020-08-252024-11-26Kite Pharma, Inc.T cells with improved functionality
CN113234169B (en)*2020-12-112022-11-01广州百暨基因科技有限公司 Targeting CLL1 chimeric antigen receptor and its application
CN113896795B (en)2020-12-112022-07-15广州百暨基因科技有限公司anti-CLL1 antibodies and uses thereof
US20240325535A1 (en)*2021-11-112024-10-03The Trustees Of The University Of PennsylvaniaCompositions and methods comprising car t cells comprising prdm1 and/or nr4a3 knockout
KR102521500B1 (en)*2021-12-022023-04-14한국화학연구원Immune cells with enhanced efficacy
CN114350665A (en)*2022-01-192022-04-15上海优替济生生物医药有限公司IFN-gamma inhibitors and uses thereof
CN114404592A (en)*2022-02-092022-04-29复旦大学附属中山医院 Application of TET2 as a target in the treatment of ischemic vascular disease
WO2024059834A2 (en)*2022-09-152024-03-21H. Lee Moffitt Cancer Center And Research Institute Inc.Downregulating inos to increase car-t killing

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication numberPriority datePublication dateAssigneeTitle
MX2018003353A (en)*2015-09-172018-09-17Novartis Ag THERAPIES WITH CART CELLS WITH IMPROVED EFFECTIVENESS.

Also Published As

Publication numberPublication date
JP2023082071A (en)2023-06-13
RU2019133286A3 (en)2021-12-07
RU2019133286A (en)2021-04-22
AU2018240295A1 (en)2019-10-10
CA3057306A1 (en)2018-09-27
KR20190127892A (en)2019-11-13
BR112019019426A2 (en)2020-05-26
IL269412A (en)2019-11-28
JP2020513828A (en)2020-05-21
US20200087376A1 (en)2020-03-19
CN110831619A (en)2020-02-21
WO2018175733A1 (en)2018-09-27
EP3600392A1 (en)2020-02-05

Similar Documents

PublicationPublication DateTitle
SG11201908719QA (en)Biomarkers and car t cell therapies with enhanced efficacy
SG11201900885VA (en)Treatment of cancer using a chimeric antigen receptor in combination with an inhibitor of a pro-m2 macrophage molecule
SG11201804086VA (en)Methods and compositions for nucleic acid analysis
SG11201807489PA (en)Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
SG11201906192SA (en)Methods of treating cancer with anti-pd-1 antibodies
SG11201808990QA (en)Compositions for topical application of compounds
SG11201807176XA (en)TGFß1-BINDING IMMUNOGLOBULINS AND USE THEREOF
SG11201907753TA (en)Bispecific binding molecules that are capable of binding cd137 and tumor antigens, and uses thereof
SG11201909955XA (en)Formulations of anti-lag3 antibodies and co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
SG11201906200WA (en)Nucleic acid-polypeptide compositions and methods of inducing exon skipping
SG11201810927QA (en)Pd-l1-specific antibodies and methods of using the same
SG11201908787WA (en)Novel bispecific antigen binding molecules capable of specific binding to cd40 and to fap
SG11201811431VA (en)Multispecific antibodies against cd40 and cd137
SG11201900677SA (en)Combination therapies of chimeric antigen receptors adn pd-1 inhibitors
SG11201900480YA (en)Anti-tim-3 antibodies
SG11201810933QA (en)Anti-c5 antibodies and uses thereof
SG11201803920TA (en)Compounds and compositions useful for treating disorders related to ntrk
SG11201808196UA (en)Neoantigens and methods of their use
SG11201900772YA (en)Gene editing of car-t cells for the treatment of t cell malignancies with chimeric antigen receptors
SG11201906319XA (en)Compositions and methods for the depletion of cd137+ cells
SG11201803701YA (en)Methods and compositions for gene editing in hematopoietic stem cells
SG11201809751XA (en)Egfr inhibitor compounds
SG11201806624XA (en)Deposition of molybdenum thin films using a molybdenum carbonyl precursor
SG11201805709RA (en)Anti-pro/latent myostatin antibodies and methods of use thereof
SG11201906853QA (en)Anti-rsv monoclonal antibody formulation

[8]ページ先頭

©2009-2025 Movatter.jp